Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMDX 2011P

Drug Profile

AMDX 2011P

Alternative Names: Alpha synucleinopathies targeted small molecule retinal tracer; AMDX-2011-P; AMDXP-2011-P; TAR DNA binding protein 43 targeted small molecule retinal tracer

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amydis
  • Developer Amydis; University of California, San Diego
  • Class Contrast media; Diagnostic agents; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cerebral amyloid angiopathy; Open-angle glaucoma
  • Phase I Amyotrophic lateral sclerosis; Parkinson's disease
  • Research Alzheimer's disease; Neurodegenerative disorders

Most Recent Events

  • 01 Mar 2024 Phase-II clinical trials in Cerebral amyloid angiopathy (Diagnosis) in USA (IV) (NCT05709314)
  • 02 Feb 2023 Amydis in collaboration with National Institutes of Health plans a phase I/II trial for Cerebral amyloid angiopathy (In adults, In the elderly) in USA (IV) in February 2023 (NCT05709314)
  • 24 Aug 2022 Phase-I clinical trials in Amyotrophic lateral sclerosis (Diagnosis) in USA (IV) (NCT05542576)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top